Telesis Bio, Inc. (TBIO)

Market Cap	3.81M
Revenue (ttm)	19.57M
Net Income (ttm)	-51.87M
Shares Out	1.77M
EPS (ttm)	-30.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,661
Open	2.370
Previous Close	2.425
Day's Range	2.030 - 2.370
52-Week Range	1.270 - 16.200
Beta	1.76
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Telesis Bio

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2011
• Employees: 147
• Stock Exchange: OTCMKTS
• Ticker Symbol: TBIO

Financial Performance

In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.